However, evidence suggests that combining PD-1/PD-L1 inhibitors with other therapeutic modalities offers promising results [6, 7, 18, 19]. This study explored the efficacy of PD-1 inhibitors combined with chemotherapy as a second-line salvage therapy for refractory EBV+ DLBCL. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.